Business Context and Reporting Period
This Form 8-K is filed by Conversion Labs, Inc. (not Lifemd, Inc.) for the reporting period of May 7, 2020. The filing details corporate actions regarding the amendment and subsequent cashless exercise of warrants issued to Alpha Capital Anstalt and Brio Master Fund.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on equity transactions.
- Alpha Warrant Exercise: Issuance of 1,957,331 shares of common stock via cashless exercise.
- Brio Warrant Exercise: Issuance of 611,666 shares of common stock via cashless exercise.
- Total Shares Issued: 2,568,997 shares.
Material Changes
The primary material change is the increase in outstanding common stock due to the full cashless exercise of the 2019 Alpha and 2019 Brio Warrants. Prior to exercise, the warrant terms were amended to increase the number of shares purchasable under anti-dilution provisions:
- Alpha Warrant: Increased by 1,657,005 shares (aggregate cap of 5,444,444 shares).
- Brio Warrant: Increased by 517,814 shares (aggregate cap of 1,701,389 shares).
Following the cashless exercise, both warrant agreements are no longer in force or effect.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general business risks. The only contingency noted is the completion of the warrant amendments and exercises, which have been finalized as of the report date.
Investor Verification Checklist
- Verify the total number of shares issued (2,568,997) and the resulting dilution impact on existing shareholders.
- Confirm that the 2019 Alpha and 2019 Brio Warrants are fully extinguished and no further obligations exist.
- Review the anti-dilution provisions that triggered the warrant amendments to understand the valuation assumptions used.
- Check subsequent filings for the updated share count and capitalization table.